Guidelines For Basic Science
Copyright ©2012 Baishideng. All rights reserved.
World J Virol. Jun 12, 2012; 1(3): 79-90
Published online Jun 12, 2012. doi: 10.5501/wjv.v1.i3.79
Selection of RNAi-based inhibitors for anti-HIV gene therapy
Stefanie A Knoepfel, Mireille Centlivre, Ying Poi Liu, Fatima Boutimah, Ben Berkhout
Stefanie A Knoepfel, Mireille Centlivre, Ying Poi Liu, Fatima Boutimah, Ben Berkhout, Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
Author contributions: Knoepfel SA and Centlivre M contributed equally to this work; Knoepfel SA, Centlivre M and Berkhout B drafted the manuscript and figures; all authors contributed in discussions, data collection and drafting of Table 1.
Supported by The NWO-CW (Chemical Sciences), ZonMw (Medical Sciences), and the Dutch AIDS Fund (project 2006006); the DAAD (German Academic Exchange Service); the FRM (Fondation pour la Recherche Medicale)
Correspondence to: Ben Berkhout, PhD, Professor, Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam, Academic Medical Center of the University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands. b.berkhout@amc.uva.nl
Telephone: +31-20-5664822 Fax: +31-20-6916531
Received: October 9, 2011
Revised: February 16, 2012
Accepted: May 20, 2012
Published online: June 12, 2012
Abstract

In the last decade, RNA interference (RNAi) advanced to one of the most widely applied techniques in the biomedical research field and several RNAi therapeutic clinical trials have been launched. We focus on RNAi-based inhibitors against the chronic infection with human immunodeficiency virus type 1 (HIV-1). A lentiviral gene therapy is proposed for HIV-infected patients that will protect and reconstitute the vital immune cell pool. The RNAi-based inhibitors that have been developed are short hairpin RNA molecules (shRNAs), of which multiple are needed to prevent viral escape. In ten distinct steps, we describe the selection process that started with 135 shRNA candidates, from the initial design criteria, via testing of the in vitro and in vivo antiviral activity and cytotoxicity to the final design of a combinatorial therapy with three shRNAs. These shRNAs satisfied all 10 selection criteria such as targeting conserved regions of the HIV-1 RNA genome, exhibiting robust inhibition of HIV-1 replication and having no impact on cell physiology. This combinatorial shRNA vector will soon move forward to the first clinical studies.

Keywords: Human immunodeficiency virus type 1; RNA interference; Gene therapy; “Human Immune System” mouse; Lentivirus